Long-term outcomes after a strategy of percutaneous coronary intervention of the infarct-related artery with drug-eluting stents or bare metal stents vs medical therapy alone in the Occluded Artery Trial (OAT)

American Heart Journal

Volumn 163, Issue 6, 2012, Pages 1011-1018

  Freixa, Xavier ^a   Džavík, Vladimír ^a   Forman, Sandra A ^b   Rankin, James M ^c   Buller, Christopher E ^d   Cantor, Warren J ^e   Ruzyllo, Witold ^f   Reynolds, Harmony R ^g   Lamas, Gervasio A ^h   Hochman, Judith S ^g  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b Clinical Trials & Surveys Corp   (United States)

^c ROYAL PERTH HOSPITAL   (Australia)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

^f INSTITUTE OF CARDIOLOGY   (Poland)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; SPIRONOLACTONE; THIENOPYRIDINE DERIVATIVE;

ADULT; ANGINA PECTORIS; ARTICLE; BARE METAL STENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HEART REINFARCTION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; STENT THROMBOSIS; TREATMENT OUTCOME;

ADULT; AGED; ANGIOPLASTY, BALLOON, CORONARY; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY OCCLUSION; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; STENTS;

EID: 84862552542     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2012.03.008     Document Type: Article

References (20)

1. Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 2006;355:2395-407. (Pubitemid 44911017)
2. Hochman JS, Reynolds HR, Dzavik V, et al. Long-term effects of percutaneous coronary intervention of the totally occluded infarctrelated artery in the subacute phase after myocardial infarction. Circulation 2011;124:2320-8.
3. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80. (Pubitemid 34586912)
4. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxeleluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31. (Pubitemid 38067635)
5. Dzavik V, Buller CE, Devlin G, et al. Angiographic and clinical outcomes of drug-eluting versus bare metal stent deployment in the Occluded Artery Trial. Catheter Cardiovasc Interv 2009;73:771-9.
6. Hochman JS, Lamas GA, Knatterud GL, et al. Design and methodology of the Occluded Artery Trial (OAT). Am Heart J 2005;150:627-42. (Pubitemid 41396490)
7. Dzavik V, Buller CE, Lamas GA, et al. Randomized trial of percutaneous coronary intervention for subacute infarct-related coronary artery occlusion to achieve long-term patency and improve ventricular function: the Total Occlusion Study of Canada (TOSCA)-2 trial. Circulation 2006;114:2449-57. (Pubitemid 44901517)
8. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33. (Pubitemid 32772726)
9. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation 2007;116:2634-53. (Pubitemid 350182388)
10. Piccolo R, Cassese S, Galasso G, et al. Long-term safety and efficacy of drug-eluting stents in patients with acute myocardial infarction: A meta-analysis of randomized trials. Atherosclerosis.
11. Rahel BM, Laarman GJ, Kelder JC, et al. Three-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomized comparison of bare-metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (Primary Stenting of Totally Occluded Native Coronary Arteries [PRISON] II study). Am Heart J 2009;157:149-55.
12. Ma J, Yang W, Singh M, et al. Meta-analysis of long-term outcomes of drug-eluting stent implantations for chronic total coronary occlusions. Heart Lung 2011;40:e32-40.
13. Gravely-Witte S, De Gucht V, Heiser W, et al. The impact of angina and cardiac history on health-related quality of life and depression in coronary heart disease patients. Chronic Illn 2007;3:66-76. (Pubitemid 47434425)
14. Andrell P, Ekre O, Grip L, et al. Fatality, morbidity and quality of life in patients with refractory angina pectoris. Int J Cardiol 2009.
15. Arnold SV, Morrow DA, Lei Y, et al. Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial. Circ Cardiovasc Qual Outcomes 2009;2:344-53.
16. Moretti C, Biondi-Zoccai GG, Sciuto F, et al. Appraising the pathophysiologic impact of coronary collaterals as measured by fractional flow reserve on symptoms and signs of myocardial ischemia. J Cardiovasc Med (Hagerstown) 2008;9:1120-6.
17. Berry C, Balachandran KP, L'Allier PL, et al. Importance of collateral circulation in coronary heart disease. Eur Heart J 2007;28:278-91.
18. Steg PG, Kerner A, Mancini GB, et al. Impact of collateral flow to the occluded infarct-related artery on clinical outcomes in patients with recent myocardial infarction: a report from the randomized occluded artery trial. Circulation 121:2724-30.
19. Garg S, Serruys P, Onuma Y, et al. 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2009;2:1190-8.
20. Garg S, Serruys PW, Miquel-Hebert K. Four year clinical follow up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT II trial. Catheter Cardiovasc Interv.